Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1
Martin Hoenigl

, Sonia Jain, David Moore, Deborah Collins, Xiaoying Sun, Peter L. Anderson, Katya Corado, Jill S. Blumenthal, Eric S. Daar, Joel Milam, Michael P. Dubé, Sheldon Morris, and for the California Collaborative Treatment Group 595 Team
Author affiliations: Medical University of Graz, Graz, Austria (M. Hoenigl); University of California, San Diego, California, USA (M. Hoenigl, S. Jain, D. Moore, X. Sun, J.S. Blumenthal, S. Morris); Department of Health and Human Services, Long Beach, California, USA (D. Collins); University of Anschutz Medical Campus, Aurora, Colorado, USA (P.L. Anderson); Harbor UCLA Medical Center, Torrance, California, USA (K. Corado, E.S. Daar); University of Southern California Keck School of Medicine, Los Angeles, California, USA (J. Milam, M.P. Dubé)
Main Article
Figure 1
Figure 1. Flow chart for selection of patients from randomized controlled trial for study of substance use and adherence to HIV preexposure prophylaxis among men who have sex with men and transgender women, February 2104–February, 2016, California, USA.
Main Article
Page created: November 14, 2018
Page updated: November 14, 2018
Page reviewed: November 14, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.